Ask AI
ProCE Banner Activity

SAVANNAH Subset: Savolitinib ± Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib

Conference Coverage
Slideset

In a randomized subset from the phase II SAVANNAH trial, the combination of savolitinib with osimertinib vs savolitinib with placebo yielded improved efficacy outcomes as well as promising CNS activity in patients with EGFR-mutant advanced NSCLC and MET overexpression and/or amplification after progression on first-line osimertinib.

Released: June 04, 2025

Expiration: December 03, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar